Results 81 to 90 of about 22,433 (204)
Oral naltrexone maintenance treatment for opioid dependence.
, 2011 Opioid dependence is considered to be a lifelong, chronic relapsing disorder. Substantial therapeutic efforts are needed to keep people drug free. Methadone treatment plays a vital role in detoxification or maintenance programs but some individuals who ...
Silvia Minozzi +11 more
core +1 more source
Obesity Reviews, Volume 27, Issue 7, July 2026.ABSTRACT Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling.
Ana Raimunda Dâmaso +7 more
wiley +1 more source
Memantine enhances the inhibitory effects of naltrexone on ethanol consumption
, 2008 Effects of the opioid receptor antagonist naltrexone (0.1; 0.3; 1.0 mg/kg i.p.) on operant ethanol self-administration alone and in combination with the non-competitive NMDA antagonist memantine (0.5 and 1 mg/kg, i.p.) were studied in rats.
Kuzmin, A, Stenback, T, Liljequist, S
core +1 more source
Obesity Reviews, Volume 27, Issue 7, July 2026.ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the effects of antiobesity agents on the distribution of body fat. Methods The PubMed, Embase, and Cochrane Library databases were reviewed for randomized controlled trials ...
Xiuqi Qiao +4 more
wiley +1 more source
Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers
Advanced Functional Materials, Volume 36, Issue 44, 1 June 2026.A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley +1 more source
, 1993 BACKGROUND/AIMS: Naltrexone has been proposed as a possible treatment of pruritus in cholestasis.These studies were undertaken to evaluate the effect of liver cirrhosis on the plasma time-course of naltrexone.
FERRARI, Anna +5 more
core
Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
Chronic Diseases and Translational Medicine, Volume 12, Issue 2, Page 100-112, June 2026.Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy +3 more
wiley +1 more source
Liver International Communications, Volume 7, Issue 2, June 2026.ABSTRACT Background and Aims Pruritus is a debilitating, under‐prioritized symptom of primary biliary cholangitis (PBC). This study assessed its impact on healthcare resource utilization (HCRU) and costs in the US. Methods A retrospective cohort study of individuals with PBC was conducted using Komodo's claims and laboratory data between September 1 ...
Robert G. Gish +8 more
wiley +1 more source
, 1995 The procedures of naltrexone treatment for the maintenance of a drug-free state from opioids are described. Treatment with naltrexone (a competitive antagonist of the opioid receptors with oral activity and long duration of action) must be employed in ...
E. Sternieri, FERRARI, Anna
core
Obesity, Volume 34, Issue S1, Page 134-143, June 2026.ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman +7 more
wiley +1 more source